Short Interest in electroCore, Inc. (NASDAQ:ECOR) Increases By 64.1%

electroCore, Inc. (NASDAQ:ECOR) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 43,000 shares, a growth of 64.1% from the October 15th total of 26,200 shares. Based on an average trading volume of 50,200 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.8% of the shares of the stock are short sold.

Institutional Trading of electroCore

Several hedge funds and other institutional investors have recently modified their holdings of ECOR. International Assets Investment Management LLC boosted its position in electroCore by 27.9% during the second quarter. International Assets Investment Management LLC now owns 67,820 shares of the company’s stock valued at $436,000 after purchasing an additional 14,800 shares during the last quarter. Renaissance Technologies LLC boosted its position in electroCore by 3.4% during the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after purchasing an additional 2,270 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in electroCore during the third quarter valued at $255,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

electroCore Stock Down 19.6 %

Shares of NASDAQ ECOR opened at $10.94 on Friday. The stock has a market capitalization of $70.56 million, a price-to-earnings ratio of -5.98 and a beta of 0.56. The stock’s fifty day simple moving average is $8.89 and its 200 day simple moving average is $7.22. electroCore has a 52-week low of $5.02 and a 52-week high of $14.20.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.